A new drug (OCT-980) for inherited retinitis pigmentosa caused by rhodopsin gene changes

You may qualify if

• Phase 1b/2 is active. Inclusion Phase 1b/2 (Multiple Ascending Dose Escalation in RHO-adRP Patients) Inclusion:; Participants must have a diagnosis of Rhodopsin-associated, autosomal dominant Retinitis Pigmentosa confirmed by a genetic test that is implemented in accordance with the relevant national requirements; Male or female greater than or equal to age 18 (inclusive) at the time of signing the informed consent form; Have a body weight >50kg, with a body mass index (BMI) from 18.0 to 35.0 kg/m^2 (inclusive) at screening; Best Corrected Visual Acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) > 55; Other than their diagnosis of RHO-adRP, be in good general health, as determined by the Investigator; Have sufficient venous access to allow blood sampling for pharmacokinetic analysis and safety laboratory samples Phase 1b/2 (Multiple Ascending Dose Escalation in RHO-adRP Patients) Exclusion:; Females who are pregnant or breastfeeding; Evidence of any other significant ocular (other than RHO-adRP) and non-ocular disease/ disorder; Lifetime history of ocular surgery; Any prior or current ophthalmologic gene therapy; Has a history of major surgery, severe trauma, or bone fracture within 12 weeks before the first dose of the investigational product or planned surgery within 4 weeks after the end of the study